A Decision Score provides prognostic discrimination for 10-year locoregional recurrence, with rising score associated with ...

Adjuvant radiotherapy reduces the risk for short-term recurrence in patients with early breast cancer, but it may have no impact on long-term recurrence or overall survival, based on a 30-year ...

When hepatocellular carcinoma (HCC) is centrally adherent to major vessels, radiotherapy administered after surgery improves outcomes even in the setting of negative surgical margins, according to a ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced muscle-invasive bladder cancer had lower risk for local recurrence with adjuvant ...

Adjuvant radiation and endocrine therapy significantly reduce locoregional recurrence in early-stage breast cancer post-lumpectomy, especially in low-risk patients. Radiation therapy notably decreases ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved cemiplimab-rwlc for adjuvant treatment of adults with cutaneous squamous cell carcinoma at ...

Adjuvant chemoradiation with weekly cisplatin did not significantly improve survival outcomes — but did increase toxicities — compared with adjuvant radiotherapy alone in women with early-stage ...

Adjuvant radiotherapy (RT) after radical prostatectomy did not improve outcomes in prostate cancer as compared with salvage RT but added toxicity, according to long-term follow-up from a randomized ...

Low-risk patients did not appear to benefit from adjuvant radiation. Adjuvant radiation therapy (RT) after radical prostatectomy may offer greater benefit than early salvage RT in men with high-risk ...

Results from the NRG Oncology GOG-0263 Phase III clinical trial testing the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for ...

Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: A phase 2 randomized clinical trial. This is an ASCO Meeting Abstract from the 2025 ...